Rifaximin Use Linked to Daptomycin Resistance: Implications for Antibiotic Stewardship

By João L. Carapinha

October 25, 2024

The article published in Nature, titled “Rifaximin Prophylaxis Causes Resistance to the Last-Resort Antibiotic Daptomycin,” reveals critical findings regarding the use of rifaximin and its impact on antibiotic resistance, particularly concerning the last-resort antibiotic daptomycin. This study suggests that the use of rifaximin, commonly administered to prevent hepatic encephalopathy in patients with liver disease, may inadvertently contribute to the emergence of resistance against daptomycin.

Key Findings:

Rifaximin, a commonly prescribed antibiotic for liver disease, has been found to cause resistance to daptomycin. This is a critical finding as daptomycin is considered a last-resort antibiotic for treating infections caused by vancomycin-resistant enterococcus faecium (VRE), a dangerous superbug.

This is the first recorded instance of one antibiotic causing resistance to another in a different class. Previously, it was believed that antibiotic resistance was limited to the specific antibiotic being used.

Rifaximin was previously considered a “low risk” antibiotic in terms of resistance development. This study challenges that assumption and highlights the unexpected consequences of antibiotic use.

Specific mutations in the rpoB gene of VRE are responsible for this cross-resistance. These mutations are becoming increasingly prevalent globally, coinciding with the increased use of rifaximin.

Rifaximin exposure leads to the upregulation of the prdRAB operon in VRE. It results in cell membrane changes that reduce daptomycin binding and efficacy. This newly identified mechanism is independent of previously known daptomycin resistance mechanisms.

This research highlights the unintended consequences of using rifaximin prophylactically. Notably, its role in promoting resistance to critical antibiotics like daptomycin. Such findings carry significant implications for public health and antibiotic stewardship, highlighting the urgent need for careful management of antibiotic use to reduce the development of antibiotic resistance. The interplay between rifaximin and daptomycin resistance emphasizes the importance of ongoing monitoring and evaluation of antibiotic prescribing practices.

Reference url

Recent Posts

neoadjuvant chemotherapy ovarian cancer
       

Neoadjuvant Chemotherapy: Transforming Treatment for Advanced Ovarian Cancer

🚀 Neoadjuvant chemotherapy is reshaping the landscape of advanced epithelial ovarian cancer treatment!

This method not only improves disease management but marks a significant shift from traditional approaches. With ongoing studies highlighting its efficacy and the importance of supportive care, it’s crucial to address both patient and caregiver needs.

Explore the latest insights on treatment patterns, survival outcomes, and the need for greater patient involvement in decisions that affect their health.

#SyenzaNews #OvarianCancer #HealthcareInnovation

rifaximin antibiotic resistance
     

Rifaximin Use Linked to Daptomycin Resistance: Implications for Antibiotic Stewardship

🚨 Important findings alert!

A recent article in Nature unveils critical insights into the unintended consequences of rifaximin use, particularly its role in fostering resistance to the crucial antibiotic daptomycin. This research highlights the need for careful antibiotic stewardship to combat the rise of antibiotic-resistant infections. 🌍

Jump into these results and their implications for public health!

#SyenzaNews #AntibioticResistance #PublicHealth

Equitable AI Healthcare
      

Global Equitable AI Healthcare: Grant Initiatives and Innovations

🌍 Exciting news from the South African Medical Research Council!

The “Grand Challenges: Catalysing Equitable AI Use for Improved Global Health” initiative is empowering over 50 researchers to address pressing healthcare issues. With a focus on equitable AI, this program aims to ensure accessible healthcare solutions for underserved populations worldwide. Discover how local innovation and global collaboration can transform health outcomes!

#SyenzaNews #GlobalHealth #AIforGood

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER




SERVICES

© 2024 Syenza™. All rights reserved.